| dc.contributor.author | Chan, Arlene | |
| dc.contributor.author | Buyse, M. | |
| dc.contributor.author | Yao, B. | |
| dc.date.accessioned | 2017-01-30T13:54:29Z | |
| dc.date.available | 2017-01-30T13:54:29Z | |
| dc.date.created | 2016-05-15T19:30:29Z | |
| dc.date.issued | 2016 | |
| dc.identifier.citation | Chan, A. and Buyse, M. and Yao, B. 2016. Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply. The Lancet Oncology. 17 (5): pp. e176-e177. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/36236 | |
| dc.identifier.doi | 10.1016/S1470-2045(16)30018-3 | |
| dc.publisher | The Lancet Publishing Group | |
| dc.title | Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply | |
| dc.type | Journal Article | |
| dcterms.source.volume | 17 | |
| dcterms.source.number | 5 | |
| dcterms.source.startPage | e176 | |
| dcterms.source.endPage | e177 | |
| dcterms.source.issn | 1470-2045 | |
| dcterms.source.title | The Lancet Oncology | |
| curtin.department | Curtin Medical School | |
| curtin.accessStatus | Fulltext not available | |
